This company has been acquired
DICE Therapeutics Past Earnings Performance
Past criteria checks 0/6
DICE Therapeutics's earnings have been declining at an average annual rate of -51%, while the Pharmaceuticals industry saw earnings growing at 16% annually.
Key information
-51.03%
Earnings growth rate
48.63%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.95% |
| Revenue growth rate | n/a |
| Return on equity | -20.08% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate
May 14
DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher
Oct 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11DICE Therapeutics GAAP EPS of -$0.58
Aug 11DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs
Jul 18Revenue & Expenses Breakdown
How DICE Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -104 | 32 | 24 |
| 31 Mar 23 | 0 | -91 | 28 | 0 |
| 31 Dec 22 | 0 | -84 | 26 | 0 |
| 30 Sep 22 | 0 | -77 | 23 | 0 |
| 30 Jun 22 | 0 | -74 | 21 | 0 |
| 31 Mar 22 | 1 | -59 | 16 | 0 |
| 31 Dec 21 | 1 | -49 | 12 | 0 |
| 30 Sep 21 | 1 | -40 | 9 | 0 |
| 30 Jun 21 | 2 | -29 | 7 | 0 |
| 31 Mar 21 | 1 | -27 | 5 | 0 |
| 31 Dec 20 | 1 | -24 | 5 | 0 |
| 31 Dec 19 | 6 | -13 | 4 | 0 |
Quality Earnings: DICE is currently unprofitable.
Growing Profit Margin: DICE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DICE is unprofitable, and losses have increased over the past 5 years at a rate of 51% per year.
Accelerating Growth: Unable to compare DICE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DICE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-16.4%).
Return on Equity
High ROE: DICE has a negative Return on Equity (-20.08%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/10 11:52 |
| End of Day Share Price | 2023/08/08 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DICE Therapeutics, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Edward Nash | Canaccord Genuity |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |